Entyvio 300 MG vials
Ended Awarded Last action
- Contract number
- SPE2DR26FHNQ4
- Awardee
-
DMS Pharmaceutical Group Inc. UEI PX72BSBQTKJ3
- Awarding agency
-
Defense Logistics Agency
Department of Defense
- Obligated
- $19,523
Award facts
- Contract value 100% obligated
- $19,522.72 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 424210 Drugs and Druggists' Sundries Merchant Wholesalers
- PSC
- 6505 Drugs And Biologicals
- Set-aside
- No set-aside
- Competition
- Full and Open Competition Negotiated Proposal / Quote
- Pricing
- Firm Fixed Price
- Place of performance
- Park Ridge, IL 60068, USA
Award details come from SAM.gov/FPDS.
About this award
The Defense Logistics Agency awarded a $19,522.72 firm fixed-price delivery order to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, for the supply of Entyvio 300 mg vials. The award, issued on November 25, 2025, with an ultimate completion date of November 26, 2025, carries no set-aside designation, demonstrating the contractor's competitive capability in unrestricted federal procurement. This delivery order is issued under DMS Pharmaceutical Group's single-award Indefinite Delivery Contract with the Defense Logistics Agency's Pharmaceutical Prime Vendor Global Program Generation V (PPV-G GEN V) initiative, designated as contract SPE2DR, which was awarded on November 13, 2025, with a $499.999 billion ceiling value and a completion date of December 31, 2036.
The PPV-G GEN V represents a $30.3 billion acquisition strategy designed to provide the Department of Defense with a reliable supply of branded and generic pharmaceuticals, biologics, and medical consumables to support military healthcare facilities worldwide. DMS Pharmaceutical Group, registered in the System for Award Management since July 18, 2001, has demonstrated substantial federal contracting activity and consistent performance across multiple therapeutic categories, positioning it as a critical supplier within the Defense Logistics Agency's pharmaceutical supply chain. The company serves as one of multiple regional prime vendor contractors under this comprehensive program, enabling DLA to issue delivery orders for the diverse and specialized pharmaceutical requirements of the federal military medical system.
Quick answers
Who was awarded contract SPE2DR26FHNQ4?
SPE2DR26FHNQ4 was awarded to DMS Pharmaceutical Group Inc. by Defense Logistics Agency (Department of Defense) on November 25, 2025.
How much is contract SPE2DR26FHNQ4 worth?
The government has obligated $19,523 on SPE2DR26FHNQ4.
Is contract SPE2DR26FHNQ4 an order under another contract?
Yes. SPE2DR26FHNQ4 is a delivery order under SPE2DR25D9231, an indefinite delivery contract.
Was contract SPE2DR26FHNQ4 competed?
The extent of competition for SPE2DR26FHNQ4 was full and open competition.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award